Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MTNB Stock Forecast 2025-2026
$1.03
Current Price
$5.24M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to MTNB Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
MTNB Price Momentum
+12.0%
1 Week Change
+22.6%
1 Month Change
-87.9%
1 Year Change
+102.0%
Year-to-Date Change
-89.3%
From 52W High of $9.60
+116.8%
From 52W Low of $0.47
📊 TOP ANALYST CALLS
Did MTNB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Matinas BioPharma is one of their latest high-conviction picks.
Latest MTNB Stock Price Targets & Analyst Predictions
MTNB has shown a year-to-date change of 102.0% and a 1-year change of -87.9%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MTNB. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MTNB Analyst Ratings
0
Buy
1
Hold
0
Sell
MTNB Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $1.03
Latest MTNB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MTNB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 31, 2024 | Maxim Group | Jason McCarthy | Hold | Downgrade | $0.00 |
| Oct 11, 2023 | BTIG | Julian Harrison | Buy | Reinstates | $3.00 |
| Jan 31, 2023 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $3.00 |
| Aug 13, 2020 | Aegis Capital | Buy | Maintains | $3.50 | |
| Jan 27, 2020 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Jan 24, 2020 | SunTrust Robinson Humphrey | Buy | Initiates | $0.00 | |
| Jun 26, 2019 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Jun 26, 2019 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
| May 17, 2019 | BTIG Research | Buy | Initiates | $0.00 | |
| May 17, 2019 | BTIG | Buy | Initiates | $0.00 | |
| Feb 11, 2019 | Roth Capital | Buy | Initiates | $0.00 | |
| Nov 13, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $5.00 |
| Aug 13, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $2.00 |
| Jul 10, 2018 | Maxim Group | Jason McCarthy | Buy | Maintains | $3.00 |
| Nov 1, 2016 | Aegis Capital | Buy | Initiates | $0.00 |
Matinas Biopharma Holdings Inc. (MTNB) Competitors
The following stocks are similar to Matinas BioPharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MTNB
Matinas BioPharma
mkt cap
5.24M
Matinas Biopharma Holdings Inc. (MTNB) Financial Data
Matinas Biopharma Holdings Inc. has a market capitalization of $5.24M with a P/E ratio of -0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -192.8%.
Valuation Metrics
Market Cap
$5.24M
Enterprise Value
$317,416
P/E Ratio
-0.2x
PEG Ratio
-0.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+132.1%
Current Ratio
3.3x
Debt/Equity
43.3x
ROE
-192.8%
ROA
-64.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Matinas Biopharma Holdings Inc. (MTNB) Business Model
About Matinas Biopharma Holdings Inc.
What They Do
Develops innovative therapeutics for unmet medical needs.
Business Model
Matinas Biopharma Holdings Inc. operates as a clinical-stage biopharmaceutical company, generating revenue primarily through the development of its proprietary lipid nano-crystal delivery technology. This technology enhances the bioavailability and efficacy of pharmaceuticals, allowing for improved treatment options in infectious diseases and rare disorders. The company's business model focuses on advancing its innovative drug delivery platforms, which can optimize drug exposure and safety profiles, thereby increasing the potential market value of its therapeutics.
Additional Information
By addressing significant gaps in existing therapeutic options and focusing on complex molecules that require advanced delivery methods, Matinas Biopharma aims to transform the treatment landscape within the healthcare and pharmaceutical industries. The company is positioned to make a meaningful impact on patient outcomes and quality of life through its cutting-edge solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
32
CEO
Mr. Jerome D. Jabbour J.D.
Country
United States
IPO Year
2014
Website
www.matinasbiopharma.comMatinas Biopharma Holdings Inc. (MTNB) Latest News & Analysis
Latest News
Quick Summary
Matinas BioPharma Holdings, Inc. has appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors, effective March 11, 2025.
Why It Matters
The appointment of experienced biotech leaders to Matinas BioPharma's board can enhance governance, strategic direction, and investor confidence, potentially impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. has entered a securities purchase agreement to sell 3,300 shares of Series C Convertible Preferred Stock and warrants for $3.3 million.
Why It Matters
Matinas BioPharma secures $3.3 million in funding through a convertible preferred stock and warrant deal, enhancing liquidity and potential for growth, impacting stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025.
Why It Matters
Evelyn D'An's appointment as Chair of the Audit Committee may enhance governance and oversight, potentially boosting investor confidence in Matinas BioPharma's financial practices.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Matinas BioPharma Receives NYSE Noncompliance Notice
6 months ago
Quick Summary
Matinas BioPharma (MTNB) received a notice from NYSE American for failing to hold its annual stockholders meeting for 2024, indicating non-compliance with listing standards.
Why It Matters
Matinas BioPharma's failure to hold its annual stockholder meeting may lead to delisting from the NYSE American, raising concerns about its governance and long-term viability, impacting investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma has terminated negotiations for global rights to MAT2203, leading to an 80% workforce reduction and cessation of product development to conserve cash.
Why It Matters
Matinas BioPharma's termination of partnership negotiations and workforce reduction signals financial distress, likely impacting stock value and investor confidence negatively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Matinas BioPharma Holdings, Inc. (NYSE:MTNB) will host its Q2 2024 earnings conference call on August 14, 2024, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters
The earnings call provides insights into Matinas BioPharma's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About MTNB Stock
What is Matinas Biopharma Holdings Inc.'s (MTNB) stock forecast for 2026?
Analyst forecasts for Matinas Biopharma Holdings Inc. (MTNB) are not currently available. The stock is trading at $1.03.
Is MTNB stock a good investment in 2026?
According to current analyst ratings, MTNB has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MTNB stock?
Price predictions from Wall Street analysts for MTNB are not currently available. The stock is trading at $1.03.
What is Matinas Biopharma Holdings Inc.'s business model?
Matinas Biopharma Holdings Inc. operates as a clinical-stage biopharmaceutical company, generating revenue primarily through the development of its proprietary lipid nano-crystal delivery technology. This technology enhances the bioavailability and efficacy of pharmaceuticals, allowing for improved treatment options in infectious diseases and rare disorders. The company's business model focuses on advancing its innovative drug delivery platforms, which can optimize drug exposure and safety profiles, thereby increasing the potential market value of its therapeutics.
What is the highest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $1.03.
What is the lowest forecasted price for MTNB Matinas Biopharma Holdings Inc.?
Price targets from Wall Street analysts for MTNB are not currently available. The stock is trading at $1.03.
What is the overall MTNB consensus from analysts for Matinas Biopharma Holdings Inc.?
The overall analyst consensus for MTNB is neutral. Out of 4 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are MTNB stock price projections?
Stock price projections, including those for Matinas Biopharma Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 4:40 PM UTC